Litcius/Paper detail

Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia

Yu Akahoshi, Yasuyuki Arai, Satoshi Nishiwaki, Shuichi Mizuta, Atsushi Marumo, Naoyuki Uchida, Yoshinobu Kanda, Hitoshi Sakai, Satoru Takada, Takahiro Fukuda, Shin Fujisawa, Takashi Ashida, Junji Tanaka, Yoshiko Atsuta, Shinichi Kako

2021International Journal of Hematology14 citationsDOI

Topics & Concepts

Minimal residual diseaseMedicineHematologyOncologyInternal medicineHematopoietic stem cell transplantationTransplantationHematopoietic cellAcute lymphocytic leukemiaLymphoblastic LeukemiaPhiladelphia chromosomeDiseaseLeukemiaImmunologyStem cellHaematopoiesisChromosomal translocationGeneBiologyGeneticsChronic Myeloid Leukemia TreatmentsAcute Lymphoblastic Leukemia researchChronic Lymphocytic Leukemia Research
Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia | Litcius